Karus Therapeutics specializes in the design and development of innovative small molecule drugs that combine targeted therapy with immunotherapeutic activity to effectively treat a wide range of solid and haematological cancers. Their research and development activities focus on creating highly-selective drugs for immune/inflammatory disorders and cancer. With a strong scientific foundation in their PI3K and HDAC6 inhibitor programs, Karus has developed small molecule drugs with significant clinical and commercial potential. Their goal is to provide cancer patients with unmet medical needs access to oral small molecule cancer drugs that can also treat immune and inflammatory disorders.